SNS 314 mesylate

Biological Activity

Potent, ATP-competitive Aurora kinase inhibitor (IC₅₀ values are 3, 9 and 31 nM for Aurora C, A and B, respectively). Exhibits both in vitro and in vivo activity against human cancer cell lines and tumor xenograft models. Displays additive antiproliferative effects in combination with chemotherapeutics such as carboplatin (Cat. No. 2626), gemcitabine (Cat. No. 3259) and 5-fluorouracil (Cat. No. 3257).

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. SNS-314, a pan-Aurora kinase inhibitor, shows potent and anti-tumor activity and dosing flexibility in vivo.
   Arbitrario et al.
   Cancer Chemother. Pharmacol., 2010;65:707
2. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model.
   VanderPorten et al.
   Mol.Cancer Ther., 2009;8:930
3. Discovery of a potent and selective Aurora kinase inhibitor.
   Oslob et al.
   Bioorg.Med.Chem.Lett., 2008;18:4880

Product Datasheets